Evandro de Azambuja/LinkedIn
May 17, 2025, 14:49
Evandro de Azambuja: Overall Survival Benefit with Adjuvant Trastuzumab and Pertuzumab in Aphinity
Evandro de Azambuja, Director of Membership 2023-2025 at ESMO – European Society for Medical Oncology, shared on LinkedIn:
“Overall Survival benefit with adjuvant trastuzumab and pertuzumab in Aphinity (node positive with absolute benefit of 2.7%)! All those years of hard work are translating into improved patients outcomes!”
Read this article about Breast Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 00:02
Sep 3, 2025, 22:35
Sep 3, 2025, 22:09
Sep 3, 2025, 20:48
Sep 3, 2025, 20:35
Sep 3, 2025, 20:10
Sep 3, 2025, 19:42